S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Stocks are for suckers – try this instead (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Stocks are for suckers – try this instead (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Stocks are for suckers – try this instead (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Stocks are for suckers – try this instead (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Stocks are for suckers – try this instead (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Stocks are for suckers – try this instead (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Stocks are for suckers – try this instead (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Stocks are for suckers – try this instead (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
NASDAQ:SRNE

Sorrento Therapeutics (SRNE) Competitors

$0.29
+0.01 (+3.60%)
(As of 05/26/2023 ET)
Compare
Today's Range
$0.28
▼
$0.32
50-Day Range
$0.20
▼
$0.37
52-Week Range
$0.16
▼
$3.09
Volume
895,625 shs
Average Volume
52.69 million shs
Market Capitalization
$135.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

SRNE vs. OCGN, BCAB, GRTS, GRPH, CCCC, GMDA, PLX, ZURA, IVVD, and ADAP

Should you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include Ocugen (OCGN), BioAtla (BCAB), Gritstone bio (GRTS), Graphite Bio (GRPH), C4 Therapeutics (CCCC), Gamida Cell (GMDA), Protalix BioTherapeutics (PLX), Zura Bio (ZURA), Invivyd (IVVD), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "biological products, except diagnostic" industry.

Sorrento Therapeutics vs.

Sorrento Therapeutics (NASDAQ:SRNE) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, community ranking, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, Ocugen had 8 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 10 mentions for Ocugen and 2 mentions for Sorrento Therapeutics. Sorrento Therapeutics' average media sentiment score of 0.39 beat Ocugen's score of 0.27 indicating that Sorrento Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sorrento Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ocugen
1 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Sorrento Therapeutics has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.83, indicating that its share price is 283% more volatile than the S&P 500.

34.5% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 37.5% of Ocugen shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by insiders. Comparatively, 2.8% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ocugen has a net margin of 0.00% compared to Sorrento Therapeutics' net margin of -818.22%. Ocugen's return on equity of -86.48% beat Sorrento Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sorrento Therapeutics -818.22% -282.82% -57.64%
Ocugen N/A -86.48% -70.76%

Ocugen has lower revenue, but higher earnings than Sorrento Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$60.32 million2.25-$428.33 millionN/AN/A
Ocugen$42.62 million2.46-$81.35 million-$0.36-1.29

Sorrento Therapeutics presently has a consensus target price of $9.00, suggesting a potential upside of 3,025.00%. Ocugen has a consensus target price of $4.90, suggesting a potential upside of 958.32%. Given Sorrento Therapeutics' higher possible upside, equities analysts clearly believe Sorrento Therapeutics is more favorable than Ocugen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sorrento Therapeutics
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Ocugen
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Sorrento Therapeutics received 516 more outperform votes than Ocugen when rated by MarketBeat users. Likewise, 74.94% of users gave Sorrento Therapeutics an outperform vote while only 67.14% of users gave Ocugen an outperform vote.

CompanyUnderperformOutperform
Sorrento TherapeuticsOutperform Votes
610
74.94%
Underperform Votes
204
25.06%
OcugenOutperform Votes
94
67.14%
Underperform Votes
46
32.86%

Summary

Ocugen beats Sorrento Therapeutics on 10 of the 16 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRNE vs. The Competition

Export to Excel
MetricSorrento TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$135.90M$2.58B$4.56B$6.18B
Dividend YieldN/A2.33%2.32%6.15%
P/E RatioN/A3.9083.7912.40
Price / Sales2.25182.873,697.3386.20
Price / CashN/A16.1297.84107.27
Price / Book1.114.895.037.13
Net Income-$428.33M$53.60M$118.58M$192.91M
7 Day Performance-8.57%-0.14%1.09%0.20%
1 Month Performance-7.10%7.02%1.28%1.33%
1 Year Performance-82.22%10.14%19.53%-0.24%

Sorrento Therapeutics Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCGN
Ocugen
1.5411 of 5 stars		$0.72
flat		$4.90
+581.6%		-80.6%$162.78M$42.62M-2.0056
BCAB
BioAtla
2.5829 of 5 stars		$3.38
-3.4%		$15.67
+363.5%		+26.6%$161.13M$250,000.00-1.2756Short Interest ↓
GRTS
Gritstone bio
1.7184 of 5 stars		$1.85
-5.6%		$5.75
+210.8%		-7.6%$164.48M$19.94M-1.43193News Coverage
GRPH
Graphite Bio
1.8065 of 5 stars		$2.92
-1.0%		$3.33
+14.2%		+14.1%$169.65MN/A-1.6269
CCCC
C4 Therapeutics
1.8254 of 5 stars		$3.16
+1.6%		$9.83
+211.2%		-58.3%$155.03M$31.10M-1.18121
GMDA
Gamida Cell
2.0791 of 5 stars		$2.03
+4.1%		$7.60
+274.4%		-11.7%$150.99MN/A-3.50166Short Interest ↓
Analyst Revision
PLX
Protalix BioTherapeutics
0 of 5 stars		$2.28
+7.5%		N/AN/A$149.16M$47.64M-7.60N/A
ZURA
Zura Bio
1.6731 of 5 stars		$5.35
+0.9%		N/AN/A$144.72MN/A0.00N/AAnalyst Report
IVVD
Invivyd
1.75 of 5 stars		$1.70
+19.7%		$3.00
+76.5%		N/A$186.12MN/A-1.05N/A
ADAP
Adaptimmune Therapeutics
1.5277 of 5 stars		$1.22
-4.7%		$6.12
+401.6%		-27.0%$188.69M$27.15M-1.77494

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:SRNE) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -